Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review
Abstract
:1. Introduction
2. Materials and Methods
2.1. Search Strategy
2.2. Eligibility Criteria
2.3. Study Selection and Data Extraction
2.4. Quality Assessment
2.5. Data Synthesis
3. Results
3.1. Study Selection
3.2. Quality and Risk of Bias Assessment
3.3. Description of Included Studies
- Children and adolescents (<18 years): Studies that primarily involve children or adolescent participants or focus on issues specific to this age group;
- Adults (>20 years): These studies exclusively involve adult participants or focus on issues specific to adults with PKU;
- Mixed age groups: Studies that include participants from various age groups or do not specify a particular age range, covering a broad spectrum of PKU patients;
- Caregivers/Parents: These studies focus on the roles of caregivers or parents in managing PKU, their knowledge, and its impact on patient outcomes.
3.4. Family-Related Factors
3.4.1. Social Factors
3.4.2. Psychological and Behavioral Factors
3.4.3. Educational Factors
3.5. Patient-Specific Factors
3.5.1. Psychological and Behavioral Factors
3.5.2. Educational Factors
3.5.3. Demographic Factors
3.6. Environmental Factors
3.7. Therapy-Related Factors
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Blau, N.; van Spronsen, F.J.; Levy, H.L. Phenylketonuria. Lancet 2010, 376, 1417–1427. [Google Scholar] [CrossRef] [PubMed]
- Vockley, J.; Andersson, H.C.; Antshel, K.M.; Braverman, N.E.; Burton, B.K.; Frazier, D.M.; Mitchell, J.; Smith, W.E.; Thompson, B.H.; Berry, S.A.; et al. Phenylalanine hydroxylase deficiency: Diagnosis and management guideline. Genet. Med. 2014, 16, 188–200. [Google Scholar] [CrossRef]
- Giovannini, M.; Verduci, E.; Salvatici, E.; Paci, S.; Riva, E. Phenylketonuria: Nutritional advances and challenges. Nutr. Metab. 2012, 9, 7. [Google Scholar] [CrossRef] [PubMed]
- MacDonald, A.; Gokmen-Ozel, H.; van Rijn, M.; Burgard, P. The reality of dietary compliance in the management of phenylketonuria. J. Inherit. Metab. Dis. 2010, 33, 665–670. [Google Scholar] [CrossRef] [PubMed]
- Bilginsoy, C.; Waitzman, N.; Leonard, C.O.; Ernst, S.L. Living with phenylketonuria: Perspectives of patients and their families. J. Inherit. Metab. Dis. 2005, 28, 639–649. [Google Scholar] [CrossRef]
- Ford, S.; O’Driscoll, M.; MacDonald, A. Living with Phenylketonuria: Lessons from the PKU community. Mol. Genet. Metab. Rep. 2018, 17, 57–63. [Google Scholar] [CrossRef]
- Gokmen-Ozel, H.; Ferguson, C.; Evans, S.; Daly, A.; MacDonald, A. Does a lower carbohydrate protein substitute impact on blood phenylalanine control, growth and appetite in children with PKU? Mol. Genet. Metab. 2011, 104, S64–S67. [Google Scholar] [CrossRef]
- Uman, L.S. Systematic Reviews and Meta-Analyses. J. Can. Acad. Child Adolesc. Psychiatry 2011, 20, 57–59. [Google Scholar]
- Petticrew, M.; Roberts, H. Systematic Reviews in the Social Sciences: A Practical Guide, 1st ed.; Blackwell Pub: Malden, MA, USA; Oxford, UK, 2006; 336p. [Google Scholar]
- Medford, E.; Hare, D.J.; Wittkowski, A. Demographic and Psychosocial Influences on Treatment Adherence for Children and Adolescents with PKU: A Systematic Review. JIMD Rep. 2018, 39, 107–116. [Google Scholar]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef]
- National Institute of Health and Care Research (NIHR). Factors Affecting Adherence to a Low Phenylalanine Diet in Children with Phenylketonuria: A Systematic Review [Internet]. PROSPERO International Prospective Register of Systematic Reviews. Available online: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=412538 (accessed on 23 March 2024).
- Amir-Behghadami, M.; Janati, A. Population, Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg. Med. J. 2020, 37, 387. [Google Scholar] [CrossRef] [PubMed]
- Wolters Kluwer Health. JBI Levels of Evidence. Levels of Evidence—Effectiveness [Internet]. JBI EBP Database. Available online: https://ospguides.ovid.com/OSPguides/jbidb.htm (accessed on 23 March 2024).
- Harrison, R.; Jones, B.; Gardner, P.; Lawton, R. Quality assessment with diverse studies (QuADS): An appraisal tool for methodological and reporting quality in systematic reviews of mixed- or multi-method studies. BMC Health Serv. Res. 2021, 21, 144. [Google Scholar]
- Fehrenbach, A.M.; Peterson, L. Parental problem-solving skills, stress, and dietary compliance in phenylketonuria. J. Consult. Clin. Psychol. 1989, 57, 237–241. [Google Scholar] [CrossRef] [PubMed]
- Shulman, S.; Fisch, R.O.; Zempel, C.E.; Gadish, O.; Chang, P.N. Children with phenylketonuria: The interface of family and child functioning. J. Dev. Behav. Pediatr. 1991, 12, 315–321. [Google Scholar] [CrossRef]
- Gleason, L.A.; Michals, K.; Matalon, R.; Langenberg, P.; Kamath, S. A treatment program for adolescents with phenylketonuria. Clin. Pediatr. 1992, 31, 331–335. [Google Scholar] [CrossRef]
- McMurry, M.P.; Chan, G.M.; Leonard, C.O.; Ernst, S.L. Bone mineral status in children with phenylketonuria—Relationship to nutritional intake and phenylalanine control. Am. J. Clin. Nutr. 1992, 55, 997–1004. [Google Scholar] [CrossRef]
- Waisbren, S.E.; Hamilton, B.D.; St James, P.J.; Shiloh, S.; Levy, H.L. Psychosocial factors in maternal phenylketonuria: Women’s adherence to medical recommendations. Am. J. Public. Health 1995, 85, 1636–1641. [Google Scholar] [CrossRef]
- Schulz, B.; Bremer, H.J. Nutrient intake and food consumption of adolescents and young adults with phenylketonuria. Acta Paediatr. 1995, 84, 743–748. [Google Scholar] [CrossRef]
- Waisbren, S.E.; Rokni, H.; Bailey, I.; Rohr, F.; Brown, T.; Warner-Rogers, J. Social factors and the meaning of food in adherence to medical diets: Results of a maternal phenylketonuria summer camp. J. Inherit. Metab. Dis. 1997, 20, 21–27. [Google Scholar] [CrossRef]
- Al-Qadreh, A.; Schulpis, K.H.; Athanasopoulou, H.; Mengreli, C.; Skarpalezou, A.; Voskaki, I. Bone mineral status in children with phenylketonuria under treatment. Acta Paediatr. 1998, 87, 1162–1166. [Google Scholar] [CrossRef]
- Singh, R.H.; Kable, J.A.; Guerrero, N.V.; Sullivan, K.M.; Elsas, L.J. Impact of a camp experience on phenylalanine levels, knowledge, attitudes, and health beliefs relevant to nutrition management of phenylketonuria in adolescent girls. J. Am. Diet. Assoc. 2000, 100, 797–803. [Google Scholar] [CrossRef] [PubMed]
- Brown, A.S.; Fernhoff, P.M.; Waisbren, S.E.; Frazier, D.M.; Singh, R.; Rohr, F.; Morris, J.M.; Kenneson, A.; MacDonald, P.; Gwinn, M.; et al. Barriers to successful dietary control among pregnant women with phenylketonuria. Genet. Med. 2002, 4, 84–89. [Google Scholar] [CrossRef] [PubMed]
- MacDonald, A.; Ferguson, C.; Rylance, G.; Morris, A.; Asplin, D.; Hall, S.; Booth, I. Are tablets a practical source of protein substitute in phenylketonuria? Arch. Dis. Child. 2003, 88, 327–329. [Google Scholar] [CrossRef] [PubMed]
- Bekhof, J.; van Spronsen, F.J.; Crone, M.R.; van Rijn, M.; Oudshoorn, C.G.M.; Verkerk, P.H. Influence of knowledge of the disease on metabolic control in phenylketonuria. Eur. J. Pediatr. 2003, 162, 440–442. [Google Scholar] [CrossRef]
- Camfield, C.S.; Joseph, M.; Hurley, T.; Campbell, K.; Sanderson, S.; Camfield, P.R. Optimal management of phenylketonuria: A centralized expert team is more successful than a decentralized model of care. J. Pediatr. 2004, 145, 53–57. [Google Scholar] [CrossRef]
- Antshel, K.M.; Brewster, S.; Waisbren, S.E. Child and parent attributions in chronic pediatric conditions: Phenylketonuria (PKU) as an exemplar. J. Child. Psychol. Psychiatry 2004, 45, 622–630. [Google Scholar] [CrossRef]
- Crone, M.R.; van Spronsen, F.J.; Oudshoorn, K.; Bekhof, J.; van Rijn, G.; Verkerk, P.H. Behavioural factors related to metabolic control in patients with phenylketonuria. J. Inherit. Metab. Dis. 2005, 28, 627–637. [Google Scholar] [CrossRef]
- Ievers-Landis, C.E.; Hoff, A.L.; Brez, C.; Cancilliere, M.K.; McConnell, J.; Kerr, D. Situational analysis of dietary challenges of the treatment regimen for children and adolescents with phenylketonuria and their primary caregivers. J. Dev. Behav. Pediatr. 2005, 26, 186–193. [Google Scholar] [CrossRef]
- MacDonald, A.; Lilburn, M.; Davies, P.; Evans, S.; Daly, A.; Hall, S.K.; Hendriksz, C.; Chakrapani, A.; Lee, P. “Ready to drink” protein substitute is easier is for people with phenylketonuria. J. Inherit. Metab. Dis. 2006, 29, 526–531. [Google Scholar] [CrossRef]
- VanZutphen, K.H.; Packman, W.; Sporri, L.; Needham, M.C.; Morgan, C.; Weisiger, K.; Packman, S. Executive functioning in children and adolescents with phenylketonuria. Clin. Genet. 2007, 72, 13–18. [Google Scholar] [CrossRef]
- Olsson, G.M.; Montgomery, S.M.; Alm, J. Family conditions and dietary control in phenylketonuria. J. Inherit. Metab. Dis. 2007, 30, 708–715. [Google Scholar] [CrossRef] [PubMed]
- Durham-Shearer, S.J.; Judd, P.A.; Whelan, K.; Thomas, J.E. Knowledge, compliance and serum phenylalanine concentrations in adolescents and adults with phenylketonuria and the effect of a patient-focused educational resource. J. Hum. Nutr. Diet. 2008, 21, 474–485. [Google Scholar] [CrossRef] [PubMed]
- Ozel, H.G.; Kucukkasap, T.; Koksal, G.; Sivri, H.S.K.; Dursun, A.; Tokatli, A.; Coskun, T. Does maternal knowledge impact blood phenylalanine concentration in Turkish children with phenylketonuria? J. Inherit. Metab. Dis. 2008, 31 (Suppl. 2), S213–S217. [Google Scholar] [CrossRef] [PubMed]
- Sharman, R.; Sullivan, K.; Young, R.; McGill, J. Biochemical markers associated with executive function in adolescents with early and continuously treated phenylketonuria. Clin. Genet. 2009, 75, 169–174. [Google Scholar] [CrossRef]
- Peipert, J.; Rohr, F.; Phornphutkul, C.; Waisbren, S. Changes in Metabolic Control of Phenylketonuria in Children Attending a Summer Camp: Pre- and Postassessment of a Nutritional Intervention. ICAN Infant Child Adolesc. Nutr. 2010, 2, 117–119. [Google Scholar] [CrossRef]
- Viau, K.S.; Wengreen, H.J.; Ernst, S.L.; Cantor, N.L.; Furtado, L.V.; Longo, N. Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria. J. Inherit. Metab. Dis. 2011, 34, 963–971. [Google Scholar] [CrossRef]
- Cotugno, G.; Nicolò, R.; Cappelletti, S.; Goffredo, B.M.; Dionisi Vici, C.; Di Ciommo, V. Adherence to diet and quality of life in patients with phenylketonuria. Acta Paediatr. 2011, 100, 1144–1149. [Google Scholar] [CrossRef]
- Alaei, M.; Asadzadeh-Totonchi, G.; Gachkar, L.; Farivar, S. Family Social Status and Dietary Adherence of Patients with Phenylketonuria. Iran. J. Pediatr. 2011, 21, 379–384. [Google Scholar]
- Macdonald, A.; Nanuwa, K.; Parkes, L.; Nathan, M.; Chauhan, D. Retrospective, observational data collection of the treatment of phenylketonuria in the UK, and associated clinical and health outcomes. Curr. Med. Res. Opin. 2011, 27, 1211–1222. [Google Scholar] [CrossRef]
- Freehauf, C.; Van Hove, J.L.K.; Gao, D.; Bernstein, L.; Thomas, J.A. Impact of geographic access to care on compliance and metabolic control in phenylketonuria. Mol. Genet. Metab. 2013, 108, 13–17. [Google Scholar] [CrossRef]
- Vieira, T.A.; Nalin, T.; Krug, B.C.; Bittar, C.M.; Netto, C.B.O.; Schwartz, I.V.D. Adherence to Treatment of Phenylketonuria: A Study in Southern Brazilian Patients. J. Inborn Errors Metab. Screen. 2015, 3, 2326409815579861. [Google Scholar] [CrossRef]
- Medford, E.; Hare, D.J.; Carpenter, K.; Rust, S.; Jones, S.; Wittkowski, A. Treatment Adherence and Psychological Wellbeing in Maternal Carers of Children with Phenylketonuria (PKU). JIMD Rep. 2017, 37, 107–114. [Google Scholar] [PubMed]
- Jurecki, E.R.; Cederbaum, S.; Kopesky, J.; Perry, K.; Rohr, F.; Sanchez-Valle, A.; Viau, K.S.; Sheinin, M.Y.; Cohen-Pfeffer, J.L. Adherence to clinic recommendations among patients with phenylketonuria in the United States. Mol. Genet. Metab. 2017, 120, 190–197. [Google Scholar] [CrossRef] [PubMed]
- Riva, M.A.; Madotto, F.; Turato, M.; Salvatici, E.; Indovina, S.; Giovannini, M.; Riva, E.; Cesana, G. Work activity and phenylalanine levels in a population of young adults with classic PKU. Med. Lav. 2017, 108, 118–122. [Google Scholar] [PubMed]
- García, M.I.; Araya, G.; Coo, S.; Waisbren, S.E.; de la Parra, A. Treatment adherence during childhood in individuals with phenylketonuria: Early signs of treatment discontinuation. Mol. Genet. Metab. Rep. 2017, 11, 54–58. [Google Scholar] [CrossRef]
- Mlčoch, T.; Puda, R.; Ješina, P.; Lhotáková, M.; Štěrbová, Š.; Doležal, T. Dietary patterns, cost and compliance with low-protein diet of phenylketonuria and other inherited metabolic diseases. Eur. J. Clin. Nutr. 2018, 72, 87–92. [Google Scholar] [CrossRef]
- Iakovou, K.; Schulpis, K. The significant role of educational status in PKU patients: The beneficial effect of psychological support in depression. Int. J. Adolesc. Med. Health 2019, 33, 20180233. [Google Scholar] [CrossRef]
- Walkowiak, D.; Bukowska-Posadzy, A.; Kałużny, Ł.; Ołtarzewski, M.; Staszewski, R.; Musielak, M.; Walkowiak, J. Therapy compliance in children with phenylketonuria younger than 5 years: A cohort study. Adv. Clin. Exp. Med. 2019, 28, 1385–1391. [Google Scholar] [CrossRef]
- Burlina, A.P.; Cazzorla, C.; Massa, P.; Loro, C.; Gueraldi, D.; Burlina, A.B. The Impact of a Slow-Release Large Neutral Amino Acids Supplement on Treatment Adherence in Adult Patients with Phenylketonuria. Nutrients 2020, 12, 2078. [Google Scholar] [CrossRef]
- Teruya, K.I.; Remor, E.; Schwartz, I.V.D. Development of an inventory to assess perceived barriers related to PKU treatment. J. Patient Rep. Outcomes 2020, 4, 29. [Google Scholar] [CrossRef]
- Kenneson, A.; Singh, R.H. Natural history of children and adults with phenylketonuria in the NBS-PKU Connect registry. Mol. Genet. Metab. 2021, 134, 243–249. [Google Scholar] [CrossRef] [PubMed]
- Teruya, K.I.; Remor, E.; Schwartz, I.V.D. Factors that increase risk for poor adherence to phenylketonuria treatment in Brazilian patients. Am. J. Med. Genet. A 2021, 185, 1991–2002. [Google Scholar] [CrossRef] [PubMed]
- Borghi, L.; Salvatici, E.; Banderali, G.; Riva, E.; Giovannini, M.; Vegni, E. Psychological wellbeing in parents of children with phenylketonuria and association with treatment adherence. Minerva Pediatr. 2021, 73, 330–339. [Google Scholar] [CrossRef] [PubMed]
- Zamani, R.; Karimi-Shahanjarini, A.; Tapak, L.; Moeini, B. Improving phenylalanine and micronutrients status of children with phenylketonuria: A pilot randomized study. Orphanet J. Rare Dis. 2021, 16, 475. [Google Scholar] [CrossRef]
- Rovelli, V.; Zuvadelli, J.; Ercoli, V.; Montanari, C.; Paci, S.; Dionigi, A.R.; Scopari, A.; Salvatici, E.; Cefalo, G.; Banderali, G. PKU and COVID19: How the pandemic changed metabolic control. Mol. Genet. Metab. Rep. 2021, 27, 100759. [Google Scholar] [CrossRef]
- Walkowiak, D.; Mikołuć, B.; Mozrzymas, R.; Kałużny, Ł.; Didycz, B.; Korycińska-Chaaban, D.; Patalan, M.; Jagłowska, J.; Chrobot, A.; Starostecka, E.; et al. The Impact of the COVID-19 Pandemic on the Perception of Health and Treatment-Related Issues among Patients with Phenylketonuria in Poland-The Results of a National Online Survey. Int. J. Environ. Res. Public Health 2021, 18, 6399. [Google Scholar] [CrossRef]
- Peres, M.; Almeida, M.F.; Pinto, É.J.; Carmona, C.; Rocha, S.; Guimas, A.; Ribeiro, R.; Martins, E.; Bandeira, A.; MacDonald, A.; et al. Implementing a Transition Program from Paediatric to Adult Services in Phenylketonuria: Results after Two Years of Follow-Up with an Adult Team. Nutrients 2021, 13, 799. [Google Scholar] [CrossRef]
- Zubarioglu, T.; Hopurcuoglu, D.; Uygur, E.; Ahmadzada, S.; Oge-Enver, E.; Isat, E.; Cansever, M.S.; Kiykim, E.; Aktuglu-Zeybek, C. The Impact of Telemedicine for Monitoring and Treatment of Phenylketonuria Patients on Metabolic Outcome During Coronavirus Disease-19 Outbreak. Telemed. J. E Health 2022, 28, 258–265. [Google Scholar] [CrossRef]
- Schoen, M.S.; Singh, R.H. Plasma metabolomic profile changes in females with phenylketonuria following a camp intervention. Am. J. Clin. Nutr. 2022, 115, 811–821. [Google Scholar] [CrossRef]
- Becsei, D.; Kiss, E.; Szatmári, I.; Arató, A.; Reusz, G.; Szabó, A.J.; Bókay, J.; Zsidegh, P. A retrospective analysis of metabolic control in children with PKU in the COVID-19 era. Mol. Genet. Metab. Rep. 2022, 32, 100897. [Google Scholar]
- Firman, S.J.; Ramachandran, R.; Whelan, K. Knowledge, perceptions and behaviours regarding dietary management of adults living with phenylketonuria. J. Hum. Nutr. Diet. 2022, 35, 1016–1029. [Google Scholar] [CrossRef]
- Proserpio, C.; Pagliarini, E.; Zuvadelli, J.; Paci, S.; Re Dionigi, A.; Banderali, G.; Cattaneo, C.; Verduci, E. Exploring Drivers of Liking of Low-Phenylalanine Products in Subjects with Phenyilketonuria Using Check-All-That-Apply Method. Nutrients 2018, 10, 1179. [Google Scholar] [CrossRef]
Study | Year | Number of Participants | Participants’ Sex | Age of Participants | Level of Evidence | Study Design |
---|---|---|---|---|---|---|
Children and adolescents (<18 years) | ||||||
Fehrenbach and Peterson [16] | 1989 | 32 PKU patients | 15 female, 17 male | Ages: 16 months–16 years | 3.e | Observational study without a control group |
Shulman, Fisch, Zempel, Gadish, and Chang [17] | 1991 | 43 PKU patients | 23 female, 20 male | Ages: 2–11 years | 4.b | Cross-sectional study |
Gleason, Michals, Matalon, Langenberg, and Kamath [18] | 1992 | 16 PKU patients | 7 female, 9 male | Ages: 12–19 years | 2.d | Pre-test–post-test control group study |
Al-Qadreh et al. [23] | 1998 | 48 PKU patients | 28 female, 20 male | Ages: 3–15 years | 4.b | Cross-sectional study |
Singh, Kable, Guerrero, Sullivan, and Elsas [24] | 2000 | 13 adolescent girls with PKU | All female | Mean age = 13 ± 2 years | 2.d | Pre-test–post-test or historic/retrospective control group study |
Antshel, Brewster, and Waisbren [29] | 2004 | 30 PKU patients | Not specified | Ages: 8–16 years | 4.c | Case series |
VanZutphen et al. [33] | 2007 | 15 PKU patients | 8 female, 7 male | Age range: 8–20 years (mean age = 14.8 years) | 4.b | Cross-sectional study |
Olsson, Montgomery, and Alm [34] | 2007 | 41 PKU patients | 16 female, 25 male | 21 patients aged 8–12 years; 20 patients aged 13–19 years | 4.b | Cross-sectional study |
Sharman, Sullivan, Young, and McGill [37] | 2009 | 16 (10 PKU + 6 controls) | PKU: 2 female, 8 male; Controls: 2 female, 4 male | PKU: mean 14.4 years; Controls: mean 14.0 years | 3.c | Cohort study with control group |
Peipert, Rohr, Phornphutkul, and Waisbren [38] | 2010 | 18 PKU patients | 7 female, 11 male | Ages: 7–15 years | 3.e | Observational study without a control group |
Vieira et al. [44] | 2015 | 56 PKU patients | 25 female, 31 male | Median age: 12 years | 4.b | Cross-sectional study |
García et al. [48] | 2017 | 75 PKU patients | 33 female, 42 male | Ages: 7–13 years | 3.e | Observational study without a control group |
Walkowiak et al. [51] | 2019 | 57 PKU patients | 37 female, 20 male | Ages: 9–20 years | 3.e | Observational study without a control group |
Zubarioglu et al. [61] | 2022 | 93 PKU patients (38 on BH4 treatment, 16 on BH4+ low-Phe diet, 39 on low-Phe diet) | 41 female, 52 male | BH4 treatment group: 5.12 ± 2.8 years (range: 0.9–12.5); BH4+ low-Phe diet group: 5.6 ± 3.15 years (range: 2.6–14.4); Low-Phe diet group: 10.10 ± 7.4 years (range: 2–41) | 3.e | Observational study without a control group |
Becsei et al. [63] | 2022 | 86 PKU patients | Not specified | Age range: 0–18 years | 3.c | Cohort study with control group |
Adults (>18 years) | ||||||
Waisbren, Hamilton, St James, Shiloh, and Levy [20] | 1995 | 69 women with PKU | All female | Ages: 16–35 years | 2.c | Quasi-experimental prospectively controlled study |
Brown et al. [25] | 2002 | 24 pregnant women with PKU | All female | ≥18 years of age | 4.c | Case series |
MacDonald et al. [32] | 2006 | 27 PKU patients | 15 female, 12 male | Median age = 30 years (range 8–49 years) | 1.c | RCT |
Riva, Madotto, Turato, Salvatici, and Indovina [47] | 2017 | 20 adults with classic PKU | 13 female, 7 male | Mean age = 32.55 (±7.37) years | 3.c | Cohort study with control group |
Iakovou and Schulpis [50] | 2019 | 110 PKU patients | Not specified | Mean age = 23.5 years | 3.e | Observational study without a control group |
Burlina, Cazzorla, Massa, Loro, Gueraldi, and Burlina [52] | 2020 | 12 adult PKU patients | 7 male, 5 female | Ages: 19–38 years; mean age: 29.6 ± 6.8 years | 3.e | Observational study without a control group |
Firman, Ramachandran, and Whelan [64] | 2022 | 137 adults with PKU | 78 female, 59 male | Ages: 16–65 years; mean age: 34 years and 4 months | 4.b | Cross-sectional study |
Mixed age groups | ||||||
McMurry, Chan, Leonard, and Ernst [19] | 1992 | 26 PKU patients | Not specified | Ages: 1.9–25.5 years | 3.e | Observational study without a control group |
Schulz and Bremer [21] | 1995 | 99 PKU patients | 60 female, 39 male | Ages: 12–29 years | 3.e | Observational study without a control group |
Waisbren et al. [22] | 1997 | 25 women with PKU | All female | Ages: 11–32 years (median age = 15 years) | 3.e | Observational study without a control group |
MacDonald et al. [26] | 2003 | 21 PKU patients | 13 female, 6 male | Ages: 8–25 years | 1.c | RCT |
Camfield, Joseph, Hurley, Campbell, and Sanderson [28] | 2004 | 108 PKU patients | Not specified | Median age = 9 years | 4.b | Cross-sectional study |
Durham-Shearer, Judd, Whelan, and Thomas [35] | 2008 | 32 PKU patients | 20 female, 12 male | Ages: 13–42 years | 2.c | Quasi-experimental prospectively controlled study |
Viau et al. [39] | 2011 | 55 PKU patients | 28 female, 27 male | Ages: 6–33 years | 3.e | Observational study without a control group |
Cotugno, Nicolò, Cappelletti, Goffredo, Dionisi Vici, and Di Ciommo [40] | 2011 | 41 PKU patients | 16 female, 25 male | Ages: 3–24 years (median age 8 years) | 4.b | Cross-sectional study |
Alaei, Asadzadeh-Totonchi, Gachkar, and Farivar [41] | 2011 | 105 PKU patients | 59 female, 46 male | Ages: 1–27 years | 4.b | Cross-sectional study |
Macdonald, Nanuwa, Parkes, Nathan, and Chauhan [42] | 2011 | 125 PKU patients | 73 female, 52 male | 20 adults (18+ years) and 105 children (up to age 17) | 3.e | Observational study without a control group |
Freehauf, Van Hove, Gao, Bernstein, and Thomas [43] | 2013 | 76 PKU patients | 33 female, 43 male | 51 children, 13 adolescents, 12 young adults (<21 years) | 4.c | Case series |
Jurecki et al. [46] | 2017 | 3,772 PKU patients | Not specified | 41% adults | 4.b | Cross-sectional study |
Mlčoch, Puda, Ješina, Lhotáková, Štěrbová, and Doležal [49] | 2018 | 184 PKU patients | 89 Female, 95 Male | Mean age of PKU patients = 14.0 years (median 11; IQR 5–22) | 4.b | Cross-sectional study |
Teruya, Remor, and Schwartz [53] | 2020 | 23 PKU patients | 9 female, 14 male | Ages: 6–34 years; mean age = 18.0 ± 7.3 years | 4.b | Cross-sectional study |
Kenneson and Singh [54] | 2021 | 219 PKU patients | 78 adults (53 females, 25 males); 141 children (71 females, 70 males) | Adults: 18–52 years (median = 30 years); children: 0–22 years (median = 7.0 years) | 3.e | Observational study without a control group |
Teruya, Remor, and Schwartz [55] | 2021 | 29 PKU patients | 14 female, 15 male | Ages: 6–34 years (mean 16.4 ± 7.5 years) | 3.e | Observational study without a control group |
Rovelli et al. [58] | 2021 | 192 PKU patients | 91 female, 101 male | Mean age = 21.9 years (age range 4–65 years) | 3.e | Observational study without a control group |
Walkowiak et al. [59] | 2021 | 567 PKU patients | 296 female, 275 male | Age range: 0.17–53 years, Mean age = 14.77 ± 12.6 years | 4.b | Cross-sectional study |
Peres et al. [60] | 2021 | 55 PKU patients | 30 female, 25 male | Ages: 23.3 ± 4.3 years | 3.e | Observational study without a control group |
Schoen and Singh [62] | 2022 | 28 females with PKU | 28 female | Ages: 15–22 years | 3.c | Cohort study with control group |
Caregivers/Parents | ||||||
Bekhof et al. [27] | 2003 | 223 (161 parents + 62 patients) | Not specified | Parents of patients’ ages: 1–22 years; Patients aged 12–22 years | 3.c | Cohort study with control group |
Crone et al. [30] | 2005 | 167 parents of PKU patients | Not specified | Parents of PKU patients born between 1974 and 1995 | 4.b | Cross-sectional study |
Ievers-Landis et al. [31] | 2005 | 30 (19 caregivers + 11 children) | Not specified | Parents of patients’ ages: 1 to 20 years | 4.b | Cross-sectional study |
Ozel, Kucukkasap, Koksal, Sivri, Dursun, Tokatli, and Coskun [36] | 2008 | 144 PKU patients | 63 female, 81 male | Ages: 1–15 years | 3.e | Observational study without a control group |
Medford, Hare, Carpenter, Rust, Jones, and Wittkowski [45] | 2017 | 46 maternal carers of PKU patients | 45 female, 1 male | Ages: 22 to 66 years | 4.b | Cross-sectional study |
Borghi, Salvatici, Banderali, Riva, Giovannini, and Vegni [56] | 2021 | 91 families of PKU patients | 84 mothers, 54 fathers | Mean age: 40.8 years (SD = 7, range 23–63 years) | 4.b | Cross-sectional study |
Zamani, Karimi-Shahanjarini, Tapak, and Moeini [57] | 2021 | 44 parents/caregivers of PKU children | 23 male, 21 female | Parents of patients’ ages: 1–12 years | 1.c | RCT |
Study | Participants | Factors | Main Findings |
---|---|---|---|
Social factors | |||
Fehrenbach and Peterson [16] | Children and adolescents (<18 years) | Family structure | Compliant families had more structure and rules than noncompliant ones (high socioeconomic status: M = 55.63 vs. 44.25; low socioeconomic status: M = 57.87 vs. 52.00). |
Olsson et al. [34] | Children and adolescents (<18 years) | Parents’ marital status | Children with separated or divorced parents had higher levels, even after adjusting for confounders. |
Vieira et al. [44] | Children and adolescents (<18 years) | Living with parents | Living with both parents was protective for adherence (RR 0.59, 95% CI 0.39–0.80, p = 0.001). |
Alaei et al. [41] | Mixed age groups | Divorced and unemployed parents; number of affected children | Blood Phe levels were higher in children with divorced (p = 0.02) or unemployed parents (p = 0.03) and positively correlated with the number of affected children per family (r = 0.43, p < 0.001). Parental education, family size, and diet adherence showed no significant link. |
Crone et al. [30] | Caregivers/Parents | Parental attitudes and subjective norm Country of birth of the mother | Children’s Phe levels are lower (−103 µmol/L) when parents believe that their dietary adherence is good. Conversely, Phe levels increase (+156 µmol/L) when parents perceive relatives’ disapproval of dietary deviations and find it difficult to administer a synthetic protein substitute three times daily. The mother’s country of birth (native vs. foreign) also affects children’s Phe levels. Children of foreign-born mothers tend to have higher Phe concentrations, potentially due to language barriers, cultural differences in diet, and varying levels of adherence to medical instructions. |
Psychological and behavioral factors | |||
Fehrenbach and Peterson [16] | Children and adolescents (<18 years) | Parents’ problem-solving skills | Parents of children in good dietary control produced a higher quality verbal response (M = 1.99, SD = 0.24) than noncompliant parents. |
Antshel et al. [29] | Children and adolescents (<18 years) | Child and parent attributions | Phe levels significantly correlate with the external attribution of behavioral dysregulation (r = 0.69, p < 0.001) and academic difficulties (r = 0.52, p < 0.001). |
Ievers-Landis et al. [31] | Caregivers/Parents | Parenting strategies, Frequency difficulty affective intensity and number of formula-related and total problems | Caregivers who rated dietary problems as less frequent, difficult, and emotionally upsetting and strategies as more effective for solving problems had children with significantly lower Phe levels (all p values < 0.05). |
Medford et al. [45] | Caregivers/Parents | Perceived support from family, parental wellbeing | The inclusion of perceived support from family, parental wellbeing, and the level of child dependency in the regression model increased the percentage of variance explained from 14.7 to 34.1%. |
Borghi et al. [56] | Caregivers/Parents | Parents’ mental wellbeing | Optimal adherence to the diet was associated with parental low social functioning, a higher tendency to control anger expression, and greater somatic depressive symptoms. |
Educational factors | |||
Shulman et al. [17] | Children and adolescents (<18 years) | Parental education levels | Higher parent education levels were associated with lower blood Phe levels, with significant correlations found between blood Phe and maternal education (r = −0.27, p < 0.05) and paternal education (r = −0.28, p < 0.05). |
Gleason et al. [18] | Children and adolescents (<18 years) | Parental knowledge | Subjects who successfully completed the program had a lower baseline blood Phe concentration (13.4 mg/dL) compared to nonsuccessful subjects (17.9 mg/dL, p < 0.05). |
Olsson et al. [34] | Children and adolescents (<18 years) | Parental education levels | Statistical analysis showed no significant link between parents’ education and Phe levels. |
Vieira et al. [44] | Children and adolescents (<18 years) | Parental education levels | Patients whose mothers had 4 years of formal education or less were at greater risk of non-adherence (RR 1.59, 95% CI 1.01–2.51, p = 0.044). |
Cotugno et al. [40] | Mixed age groups | Parental education levels | Children with mothers with lower educational levels showed significant excess (median 158 mg vs. −36 mg, p = 0.045), while no difference was found based on fathers’ education (median −35.5 vs. −2.00, p = 0.9). |
Bekhof et al. [27] | Caregivers/Parents | Parental knowledge | Linear regression analysis showed that greater knowledge was associated with lower Phe concentrations, but this association was statistically significant only in the parent group (parents: b = −28, 95% CI −39/−17; patients: b = −20, 95% CI −42/2). |
Ozel et al. [36] | Caregivers/Parents | Maternal knowledge | Better maternal understanding of Phe exchange correlated with lower blood Phe in children (p < 0.05), indicating improved dietary compliance. |
Study | Participants | Factors | Main Findings |
---|---|---|---|
Psychological and behavioral factors | |||
Singh, Kable, Guerrero, Sullivan, and Elsas [24] | Children and adolescents (<18 years) | Knowledge of diet, attitudes toward disease, health beliefs | Increased knowledge, improved attitudes, and reduced negative health beliefs were not accompanied with sustained reductions in blood Phe levels. |
Antshel, Brewster, and Waisbren [29] | Children and adolescents (<18 years) | Child and parent attributions | Four vignettes compared attributional style of PKU children and their parents to children with other chronic conditions and healthy children. Children with high Phe levels attribute behavioral dysregulation to external causes (r = 0.61, p < 0.001), consistent across vignettes (r = 0.43, p < 0.001), linking Phe levels to externalizing problems. Phe levels correlate with external attribution of behavioral dysregulation (r = 0.69, p < 0.001) and academic difficulties (r = 0.52, p < 0.001). |
Waisbren, Hamilton, St James, Shiloh, and Levy [20] | Adults (>18 years) | Need for support from parents, support from health professionals, external health locus of control (chance) | Logistic regression showed that women with PKU are at higher risk for poor metabolic control lacked professional support, needed substantial parental help, and believed in chance or external locus of control (a perspective where individuals view external influences as the main drivers of their life experiences and outcomes, rather than their own actions or decisions). |
Brown et al. [25] | Adults (>18 years) | Believing that the costs of treatment add to the complications of the diet | The main findings indicated that late metabolic control is significantly associated with the belief that treatment costs exacerbate dietary complications, which has an RR of 4.2. |
Riva, Madotto, Turato, Salvatici, and Indovina [47] | Adults (>18 years) | Work schedule | Full-time employment and shift work are associated with higher mean Phe levels, exceeding 281.11 μMol/L and 356.73 μMol/L, respectively, indicating poorer metabolic compliance. |
Teruya, Remor, and Schwartz [53] | Mixed age groups | Perceived barriers related to PKU treatment. | Adolescents reported significantly fewer treatment barriers than adults (p = 0.008). Patients with better metabolic control perceived fewer barriers than those with poor adherence (p = 0.009). More perceived barriers correlated with higher Phe levels (p = 0.001). |
Ievers-Landis et al. [31] | Caregivers/Parents | Parenting strategies, Frequency difficulty affective intensity and number of formula-related and total problems, Adherence strategies | Caregivers who perceive fewer dietary problems and find their strategies effective have children with lower Phe levels (p < 0.05). Authoritarian parenting correlates with higher Phe in older children (p < 0.05). Formula-related (r = 0.51, p = 0.03) and total problems (r = 0.47, p = 0.05) positively correlate with Phe levels. Perceived management effectiveness strongly correlates with lower Phe (r = 0.64, p < 0.01), while children’s maladaptive strategies are associated with higher levels, highlighting the impacts of problem-solving and parenting on adherence. |
Educational factors | |||
Gleason, Michals, Matalon, Langenberg, and Kamath [18] | Children and adolescents (<18 years) | Patients’ PKU knowledge | Seven subjects (5M, 2F) succeeded; nine (4M, 5F) did not succeed. Groups differed only in baseline blood Phe (successful: 13.4 mg/dL; nonsuccessful: 17.9 mg/dL, p < 0.05). Successful subjects reduced levels by 2.9 mg/dL to 10.5 ± 3.8 mg/dL. Baseline levels negatively correlated with success (r = −0.485). |
Brown et al. [25] | Adults (>18 years) | Patient’s education | Late metabolic control is significantly associated with having a high school education or less, which has an RR of 8.4. |
Iakovou and Schulpis [50] | Adults (>18 years) | Patient’s education | Higher education predicted better adherence to the Phenylketonuria (PKU) diet. |
Firman, Ramachandran, and Whelan [64] | Adults (>18 years) | Patients’ PKU knowledge | Knowledge levels (general, PKU-specific, and PKU diet) were significantly associated with PKU diet adherence. Those not following their PKU diet had lower knowledge scores (69.1% ± 15.4%) than those consistently adhering (78.0% ± 12.0%, p = 0.005). |
Durham-Shearer, Judd, Whelan, and Thomas [35] | Mixed age groups | Patients’ PKU knowledge | This study found a significant improvement in knowledge scores from baseline to 1 month favoring the intervention group (p < 0.05), but this increase in knowledge did not lead to a statistically significant improvement in compliance measures. |
Demographic factors | |||
Al-Qadreh et al. [23] | Children and adolescents (<18 years) | Patients’ age and sex | Phe levels were higher in patients over 8 years old (21/26) than in younger children (3/22). Age was positively correlated with Phe concentration (r = 0.60, p < 0.001), while BD and the artificial-to-natural-protein-intake ratio showed negative correlations (r = −0.56 and r = −0.46, respectively; p < 0.001). |
VanZutphen et al. [33] | Children and adolescents (<18 years) | Patients’ age | Age was inversely correlated with dietary adherence, indicating lower adherence in older individuals (r = 2.53, p < 0.05). Both concurrent and mean lifetime Phe (Phe) levels inversely correlated with adherence (mean lifetime Phe: r = 2.60, p < 0.05; concurrent Phe: r = 2.82, p < 0.001. Concurrent Phe levels positively correlated with age (r = 0.60, p < 0.05) |
Olsson, Montgomery, and Alm [34] | Children and adolescents (<18 years) | Patients’ age and sex | Girls tended to have lower levels than boys, with borderline statistical significance. |
García et al. [48] | Children and adolescents (<18 years) | Patients’ age | Mean blood Phe (Phe) levels significantly increased in the first three years of life and between 6 and 9 years old, with a notable rise of 1.1 mg/dL from the first to the second year. Higher Phe levels at 12–23 months (OR = 1.751) and 6–8 years (OR = 1.682) were significant predictors of treatment discontinuation before age 13, explaining 29–30% of the variance in adherence. |
Brown et al. [25] | Adults (>18 years) | Patients’ age | The main findings indicate that late metabolic control is significantly associated with being under 25 years of age, with a relative risk (RR) of 8.4. |
Riva, Madotto, Turato, Salvatici, and Indovina [47] | Adults (>18 years) | Patients’ age | Age and employment status were found to impact Phe (Phe) blood levels. Each year of age increased mean Phe levels by 30.56 μMol/L (95% CI: 7.53; 53.60). |
McMurry, Chan, Leonard, and Ernst [19] | Mixed age groups | Patients’ age | Older subjects had higher Phe levels than younger groups. Only 2/26 PKU subjects had optimal levels (<300 μmol/L), while 19 had elevated levels (>600 μmol/L). Age was correlated with Phe concentration (r = 0.636, p < 0.001) and negatively correlated with dietary compliance (r = −0.689, p < 0.0001). Older subjects’ formula compliance varied (0–100%). |
Schulz and Bremer [21] | Mixed age groups | Patients’ age | Mean plasma Phe levels of the PKU patients increased with age (r = 0.35, p < 0.001). |
Viau et al. [39] | Mixed age groups | Patients’ age | Blood Phe (Phe) levels increased with age, while Phe sampling frequency decreased. Significant differences were found in Phe level consistency and mean SD among age groups (p < 0.05), with marked differences between 0 and 5 years old and both 6 and 10 and >10 years old (p < 0.001). No significant difference in SD blood Phe levels was seen between 0 and 5 and >10 years old (p = 0.932). |
Cotugno, Nicolò, Cappelletti, Goffredo, Dionisi Vici, and Di Ciommo [40] | Mixed age groups | Patients’ age and gender | Age (q = 0.03, p = 0.8) and gender did not significantly affect Phe levels (median −35.5 vs. −2.00, p = 0.9). |
Macdonald, Nanuwa, Parkes, Nathan, and Chauhan [42] | Mixed age groups | Patients’ sex | Females had higher mean proportions, with 70%+ Phe concentrations within target range vs. males: 0-5 years; Males were more responsive (nearly significant) for OR 0.42 [0.17, 1.03], 6-17 years: OR 1.67 [1.09, 2.55], and 18+ years: OR 3.92 [1.16, 13.32]. |
Freehauf, Van Hove, Gao, Bernstein, and Thomas [43] | Mixed age groups | Patients’ age and sex | Phe (Phe) levels were correlated significantly with age, increasing from adolescence to young adulthood (PheMedian ρ = 0.62), particularly in adolescents and adults (Spearman PheMedian ρ = 0.48, p = 0.014). |
Jurecki et al. [46] | Mixed age groups | Patients’ age | Non-adherence to target Phe levels increased with age. |
Mlčoch, Puda, Ješina, Lhotáková, Štěrbová, and Doležal [49] | Mixed age groups | Patients’ age | Age was the strongest predictor of Phe (Phe) levels. A linear regression model revealed a starting Phe concentration of 140 μmol/L, with an increase of 22 μmol/L per year of age (p < 0.0001). |
Kenneson and Singh [54] | Mixed age groups | Patients’ age and sex | Individuals with elevated Phe levels were mostly older females. In total, 39.5% of females vs. 21.5% of males had high Phe (p = 0.0202). Females were older (median 16.6 years) than males (median 9.6 years, p = 0.0088). No significant links were found between Phe levels and other factors studied. |
Medford, Hare, Carpenter, Rust, Jones, and Wittkowski [45] | Caregivers/Parents | Patients’ age | Age significantly influenced target blood Phe levels, explaining 14.7% (p = 0.009) and a slightly smaller but significant portion of the variance, respectively (p = 0.002) |
Study | Participants | Factors | Main Findings |
---|---|---|---|
Environmental factors | |||
Singh et al. [24] | Children and adolescents (<18 years) | Knowledge of diet | Increased knowledge was not accompanied with sustained reductions in blood Phe levels. |
Peipert et al. [38] | Children and adolescents (<18 years) | Camp-based intervention | Educational and camp-based interventions have been shown to improve adherence to a low-Phe diet in patients with PKU. |
Vieira et al. [44] | Children and adolescents (<18 years) | Distance to clinic | The distance between the patient’s town of origin and the PKU clinic did not correlate with median Phe concentration in the 12 months prior to study inclusion, both for adherent patients (p = 0.629) and non-adherent patients (p = 0.72). |
Becsei et al. (2022) [63] | Children and adolescents (<18 years) | COVID-19 pandemic | During the study, both age groups had significantly increased median Phe (Phe) levels and fewer patients achieved target Phe ranges. Significant negative correlations were found between the dried blood spot (DBS) testing frequencies and Phe levels in both age groups during NCE (children r = −0.43, p = 0.002; adolescents r = −0.37, p = 0.012), as well as in the adolescent group during CE (r = −0.6, p = 0.006). |
Waisbren et al. (1995) [20] | Adults (>18 years) | Support from health professionals | Logistic regression showed women at higher risk of poor metabolic control lacked professional support. |
Iakovou and Schulpis [50] | Adults (>18 years) | Psychological support | All the participants who were either mildly or moderately depressed experienced a beneficial effect on their depression when they were psychologically supported, which was further enforced by the reduction in Phe blood levels after their psychological support. |
Waisbren et al. (1997) [22] | Mixed age groups | Camp-based intervention | The week-long camping experiment was offered to girls and young women throughout the United States and other countries. Blood Phe levels decreased in 96% (24/25) of participants during camp and remained lower in 75% (18/24) at follow-up (p < 0.05). |
Freehauf et al. [43] | Mixed age groups | Distance to clinic | No significant correlation was found between the distance to clinic in miles and the Phe target (p = 0.62). |
Jurecki et al. [46] | Mixed age groups | Clinic staffing resources | Staffing resources, defined as the number of specialists per 100 actively managed PKU patients, were correlated with the proportion of non-adherent patients in different age groups. |
Rovelli et al. [58] | Mixed age groups, patients ≥4 years old in follow-up, divided into age subgroups: GROUP A (n = 51, <12 years old) and GROUP B (n = 141, ≥12 years old) | COVID-19 pandemic | Children from Group A showed no significant change, while adolescents and adults from Group B improved, with blood Phe levels decreasing from 556.4 ± 301 µmol/l to 454 ± 252 µmol/L. |
Walkowiak et al. [59] | Mixed age groups | COVID-19 pandemic, stress | High stress was linked to elevated Phe (p = 0.0023). Better compliance was associated with accepting remote consultations, fewer issues contacting providers, and a lower likelihood of skipping Phe tests. |
Schoen and Singh (2022) [62] | Mixed age groups | Camp-based intervention | After the camp intervention, plasma Phe concentrations decreased significantly (median change: −173 µmol/L [IQR: −325, −28 µmol/L]), and 70% of participants with PKU showed improved dietary adherence through reduced Phe intake or increased medical food consumption. |
Zamani et al. [57] | Caregivers/Parents | Educational intervention | An educational intervention significantly improved children’s Phe levels over time (F = 4.68, p = 0.03). From baseline to 24-month follow-up, children with normal levels increased from 26% to 73.9% in the educational group. |
Study | Participants | Factors | Main Findings |
---|---|---|---|
Therapy-related factors | |||
Walkowiak et al. (2019) [51] | Children and adolescents (<18 years) | Number of visits to a specialist, number of Phe blood tests | In the first year of life, PKU patients had more doctor visits (OR = 6.8267; p < 0.0001) and blood tests (OR = 2.7875; p < 0.0402) than in the second year and beyond. More specialist visits correlated with higher Phe levels (ρ = 0.39), while more Phe blood tests correlated with better dietary control (ρ = −0.33). |
Zubarioglu et al. (2022) [61] | Children and adolescents (<18 years) | Telemedicine | During the pandemic, an online monitoring system significantly improved the maintenance of Phe levels within recommended ranges for all treatment modalities. Phe washout frequency decreased, and Phe tolerance increased significantly among those on a low-Phe diet, highlighting the pandemic’s unexpected positive impact on Phe-level management. |
MacDonald et al. (2006) [32] | Adults (>18 years) | Liquid protein substitute | Using a liquid protein substitute reduced self-consciousness and improved portability, making it easier to consume away from home. Significant improvements were seen in ease of use (p < 0.0001), convenience (p = 0.002), and reduced wastage (p = 0.001). |
Burlina et al. (2020) [52] | Adults (>18 years) | Large neutral amino acid supplements | Pre-treatment, 25% reported medium and most reported low medication adherence, but 60% claimed full adherence in the last month. Post-LNAA treatment, 96% achieved full adherence. Phe levels remained stable, while Tyr levels rose significantly in 92% of patients (mean 75 ± 16 µmol/L; p = 0.0195). |
MacDonald et al. (2003) [26] | Mixed age groups | Phe-free amino acid tablets vs. powder | Compliance was higher with the new tablets compared to usual protein substitutes, with 90% adherence versus 65%. Furthermore, plasma Phe levels were lower with the amino acid tablets, showing a median difference of 46 µmol/L in blood concentrations between the groups, which was statistically significant (p = 0.02). |
Camfield et al. (2004) [28] | Mixed age groups | Treatment approach | Children aged 2–12 in Nova Scotia had better Phe control and more medical consultations than those in New Brunswick (p < 0.01). Older patients had more frequent elevated Phe levels (p = 0.01), indicating that expert, coordinated PKU management is more effective. |
Jurecki et al. (2017) [46] | Mixed age groups | Patient age, clinic staffing resources, clinic Phe target, adherence to blood frequency testing | Non-adherence to target Phe levels increased with age. Clinics using a higher upper Phe target (600 μM) for adults showed more non-adherence compared to those with a 360 μM target (p < 0.05). Adherence to target Phe levels did not correlate with adherence to or actual frequency of blood testing, except for patients who are pregnant/planning pregnancy. Staffing resources correlated with the proportion of non-adherent patients in different age groups. |
Teruya et al. (2021) [55] | Mixed age groups | Tolerance to Phe, metabolic control throughout childhood, perceived difficulty in living with demands of treatment | Classical PKU patients had significantly higher current blood Phe levels than mild PKU patients (U = 37.000, p = 0.003). Lifetime and childhood Phe levels strongly correlated with recent metabolic control. More perceived treatment barriers were associated with higher blood Phe levels (τ = 0.39, p = 0.003). |
Peres et al. (2021) [60] | Mixed age groups | Transition program from pediatric to adult services | Median blood Phe levels stayed stable (525 ± 248 µmol/L vs. 552 ± 225 µmol/L; p = 0.100), but the percentage below 480 µmol/L decreased (51% to 37%; p = 0.041). Clinic appointments increased significantly (from 5 to 11; p < 0.001). The adult service minimally affected metabolic control but maintained high attendance. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yagudina, R.; Kulikov, A.; Serpik, V.; Protsenko, M.; Kopeyka, K. Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review. Nutrients 2024, 16, 3119. https://doi.org/10.3390/nu16183119
Yagudina R, Kulikov A, Serpik V, Protsenko M, Kopeyka K. Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review. Nutrients. 2024; 16(18):3119. https://doi.org/10.3390/nu16183119
Chicago/Turabian StyleYagudina, Roza, Andrey Kulikov, Vyacheslav Serpik, Marina Protsenko, and Kirill Kopeyka. 2024. "Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review" Nutrients 16, no. 18: 3119. https://doi.org/10.3390/nu16183119
APA StyleYagudina, R., Kulikov, A., Serpik, V., Protsenko, M., & Kopeyka, K. (2024). Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review. Nutrients, 16(18), 3119. https://doi.org/10.3390/nu16183119